What is mazdutide?
Mazdutide is a drug that switches on both the GLP-1 and glucagon receptors. It was approved in China in 2025 for obesity and type 2 diabetes, the first drug of its exact type approved anywhere in the world. It is not FDA approved and is still experimental in the US, UK, Australia, and Canada. So buying it outside China means buying an unapproved research chemical.
Studies in people from the compound pages this answer belongs to
- Mazdutide
- Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1) 2025 PMID 40421736
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes 2026 PMID 41407860
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial 2026 PMID 42251595
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.